2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Adenocarcinoma, Follicular
1
Interventions
Specimen Handling
642
pembrolizumab
565
Magnetic Resonance Spectroscopy
548
Carboplatin
426
Cisplatin
377
Cyclophosphamide
374
Biopsy
365
Paclitaxel
306
Nivolumab
303
Gemcitabine
303
Radiotherapy
274
Bevacizumab
240
Dexamethasone
209
fludarabine
207
Docetaxel
191
durvalumab
183
atezolizumab
177
Oxaliplatin
174
venetoclax
168
Fluorouracil
167
Rituximab
166
Pemetrexed
164
Capecitabine
161
Radiation
159
Doxorubicin
159
Radiosurgery
150
Etoposide
137
Ipilimumab
135
Leucovorin
133
Lenalidomide
132
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sodium Iodide
×
90 days
×
Clear all
NCT01398085
2026-05-07
IoN
University College, London
Phase 2/3
Active not recruiting
504 enrolled